Volume 21, Number 11—November 2015
Research
Carbapenem-Resistant Enterobacteriaceae in Children, United States, 1999–2012
Table 2
Inpatient and outpatient CRE counts by species Enterobacteriaceae, The Surveillance Network–USA database, 1999–2012*
No. (%) isolates analyzed, n = 245,257 | No. (%) CRE isolates analyzed, n = 89 | No. (%) isolates analyzed, n = 63,880 | No. (%) CRE isolates analyzed, n = 171 | ||
---|---|---|---|---|---|
Escherichia coli | 197,807 (80.65) | 27 (29.35) | 36,139 (56.57) | 31 (18.13) | |
Proteus mirabilis | 15,738 (6.42) | 2 (2.17) | 8,747 (13.69) | 56 (32.75) | |
Klebsiella pneumoniae | 14,115 (5.76) | 22 (23.91) | 8,620 (13.49) | 70 (40.94) | |
Enterobacter species† | 8,225 (3.35) | 27 (29.35) | 4,907 (7.68) | 8 (4.68) | |
Serratia marcescens | 4,879 (1.99) | 9 (9.78) | 3,364 (5.27) | 0 | |
Citrobacter species‡ | 4,493 (1.83) | 2 (2.17) | 2,103 (3.29) | 6 (3.51) |
*CRE, carbapenem-resistant Enterobacteriaceae. CRE is defined as resistance to all tested third-generation cephalosporins (ceftriaxone, cefotaxime, or ceftazidime), and nonsusceptiblity to >1 carbapenem (ertapenem, imipenem, meropenem, or doripenem). For bacteria with intrinsic imipenem nonsusceptibility (P. mirabilis), the CRE criteria required nonsusceptibility to >2 of the carbapenems listed. ICU, intensive care unit.
†E. aerogenes and E. cloacae.
‡C. freundii and C. koseri.